{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:07:32Z","timestamp":1766182052970,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["FK 135327"],"award-info":[{"award-number":["FK 135327"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020","UIDP\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020","UIDP\/04046\/2020"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00064203\/6003","LM2018132"],"award-info":[{"award-number":["00064203\/6003","LM2018132"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003549","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jcf.2023.04.001","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:37:28Z","timestamp":1682012248000},"page":"1085-1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor\/ivacaftor combination"],"prefix":"10.1016","volume":"22","author":[{"given":"Marianna","family":"P\u00f3csi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Fejes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Bene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3397-2829","authenticated-orcid":false,"given":"Istv\u00e1n","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Milan","family":"Macek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"B\u00e9la","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.04.001_bib0001","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.04.001_bib0002","unstructured":"ECFS Patient Registry Annual Report, 2020. (https:\/\/www.ecfs.eu\/projects\/ecfs-patient-egistry\/annual-reports)."},{"key":"10.1016\/j.jcf.2023.04.001_bib0003","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.04.001_bib0004","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcf.2023.04.001_bib0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.001_bib0006","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.jcf.2023.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jcf.2023.04.001_bib0008","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"et al.; VX09-809-102 Study Group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.001_bib0009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.04.001_bib0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"VX13-809-011 part B investigator group. Lumacaftor\/ivacaftor in patients aged 6-11 years with cystic fibrosis and homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.001_bib0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2017.09.012","article-title":"VX14-809-106 Investigator Group. Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR","volume":"17","author":"Taylor-Cousar","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.001_bib0012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"French cystic fibrosis reference network study group. Real-life safety and effectiveness of Lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.001_bib0013","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","article-title":"Clinical effectiveness of Lumacaftor\/Ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A clinical trial","volume":"18","author":"Sagel","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.001_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1513\/AnnalsATS.202007-881ED","article-title":"The PROSPECT is bright for CFTR modulators","volume":"18","author":"Montemayor","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.001_bib0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.chest.2016.04.006","article-title":"Human epididymis protein 4: a novel serum inflammatory biomarker in cystic fibrosis","volume":"150","author":"Nagy","year":"2016","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.001_bib0016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2018.08.013","article-title":"Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment","volume":"18","author":"Nagy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.001_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.592184","article-title":"Enhanced expression of human epididymis protein 4 (HE4) reflecting pro-inflammatory status is regulated by CFTR in cystic fibrosis bronchial epithelial cells","volume":"12","author":"Bene","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.001_bib0018","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","article-title":"A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors","volume":"45","author":"Kirchhoff","year":"1991","journal-title":"Biol Reprod"},{"issue":"13","key":"10.1016\/j.jcf.2023.04.001_bib0019","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jcf.2023.04.001_bib0020","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1515\/cclm-2014-0041","article-title":"Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer","volume":"52","author":"Nagy","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.001_bib0021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj20020869","article-title":"A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein","volume":"368","author":"Clauss","year":"2002","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.jcf.2023.04.001_bib0022","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1515\/hsz-2016-0262","article-title":"The role of whey acidic protein four-disulfide-core proteins in respiratory health and disease","volume":"398","author":"Small","year":"2017","journal-title":"Biol Chem"},{"key":"10.1016\/j.jcf.2023.04.001_bib0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-7-61","article-title":"WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung","volume":"7","author":"Bingle","year":"2006","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.jcf.2023.04.001_bib0024","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"VX14-809-109 investigator group. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.04.001_bib0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.04.001_bib0026","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2017.01.002","article-title":"Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher","volume":"16","author":"Szczesniak","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.001_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"56","key":"10.1016\/j.jcf.2023.04.001_bib0028","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1515\/cclm-2017-0530","article-title":"Laboratory performance of sweat conductivity for the screening of cystic fibrosis","volume":"28","author":"Greaves","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.001_bib0029","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","article-title":"Predictive factors for lumacaftor\/ivacaftor clinical response","volume":"18","author":"Masson","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.001_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cca.2020.05.015","article-title":"Laboratory biomarkers for lung disease severity and progression in cystic fibrosis","volume":"508","author":"Bene","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jcf.2023.04.001_bib0031","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ppul.23712","article-title":"CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy","volume":"52","author":"Guerra","year":"2017","journal-title":"Pediatr. Pulmonol"},{"key":"10.1016\/j.jcf.2023.04.001_bib0032","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.jcf.2023.04.001_bib0033","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1515\/cclm-2021-0510","article-title":"Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics","volume":"59","author":"Lycke","year":"2021","journal-title":"Clin Chem Lab Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:09:09Z","timestamp":1762031349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1569199323000917"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"type":"print","value":"1569-1993"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor\/ivacaftor combination","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}